glucose, (beta-d)-isomer has been researched along with Compensatory Hyperinsulinemia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Karumuthil-Melethil, S; Li, R; Perez, N; Vasu, C | 1 |
| Dixen, U; Fenger, M; Goetze, JP; Holst, JJ; Jørgensen, NB; Madsbad, S; Madsen, PL; Richter, EA; Thirumathyam, R; Van Hall, G; Vejlstrup, N | 1 |
| Gustafson, KM; Kellon, EM | 1 |
| Alenina, N; Bader, M; Crespo-Garcia, S; Dechend, R; Ebrahim, M; Golic, M; Grune, J; Haase, N; Herse, F; Heuser, A; Kintscher, U; Kräker, K; Luft, FC; Müller, DN; Reichhart, N; Strauß, O | 1 |
| García, SD; Sanz, AD; Sanz, SD | 1 |
| Condren, AB; Donahue, EP; Farmer, TD; Healey, EC; Kim, K; McCoy, GA; O'Brien, TP; Printz, RL; Shiota, M; Ueta, K | 1 |
| Andrikopoulos, S; Joannides, CN; Lamont, BJ; Mangiafico, SP; Waters, MF | 1 |
| Fujimori, Y; Isaji, M; Ishikawa-Takemura, Y; Katsuno, K | 1 |
| Ichiki, H; Ishihara, E; Komatsu, Y; Kubo, M; Miura, T; Okada, M; Tanigawa, K | 1 |
| Anai, M; Arakawa, K; Asano, T; Ishirahara, T; Kikuchi, M; Nawano, M; Oku, A; Saito, A; Ueta, K; Umebayashi, I | 1 |
| Hashimoto, I; Ichiki, H; Ishida, T; Ishihara, E; Iwamoto, N; Kato, M; Komatsu, Y; Kubo, M; Miura, T; Okada, M; Tanigawa, K | 1 |
1 review(s) available for glucose, (beta-d)-isomer and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
[Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
Topics: Bariatric Surgery; Benzhydryl Compounds; Causality; Comorbidity; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Reducing; Disease Management; Evidence-Based Medicine; Exercise Therapy; Glucagon-Like Peptide 1; Glucosides; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Obesity; Practice Guidelines as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2013 |
1 trial(s) available for glucose, (beta-d)-isomer and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Glucosides; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2022 |
9 other study(ies) available for glucose, (beta-d)-isomer and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes.
Topics: Animals; Antigen-Presenting Cells; Cells, Cultured; Coculture Techniques; Crosses, Genetic; Cytokines; Diabetes Mellitus, Type 1; Female; Hyperglycemia; Hyperinsulinism; Immunity, Innate; Lectins, C-Type; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Nerve Tissue Proteins; Prediabetic State; Toll-Like Receptor 2; Zymosan | 2008 |
Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors.
Topics: Animals; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Horse Diseases; Horses; Hyperinsulinism; Hyperlipidemias; Hypertriglyceridemia; Hypoglycemic Agents; Male; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes.
Topics: Animals; Benzhydryl Compounds; C-Peptide; Cardiotonic Agents; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Heart Failure; Humans; Hyperinsulinism; Hypertension; Male; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
Topics: Animals; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucokinase; Glucose; Glucose Clamp Technique; Glucosides; Hyperglycemia; Hyperinsulinism; Immunohistochemistry; Liver; Male; Obesity; Organ Size; Oxygen Consumption; Rats; Rats, Zucker; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
Topics: Adipose Tissue, White; Adiposity; Animals; Benzhydryl Compounds; Cell Size; Gene Expression Regulation; Glucose Clamp Technique; Glucose Intolerance; Glucose Transporter Type 4; Glucosides; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Membrane Transport Modulators; Muscle, Skeletal; Phosphoenolpyruvate Carboxykinase (GTP); Rats, Transgenic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2017 |
Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Drug Administration Schedule; Female; Glucose; Glucosides; Hyperinsulinism; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Obesity; Time Factors | 2009 |
New antidiabetic compounds, mangiferin and its glucoside.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hyperinsulinism; Hypoglycemic Agents; Male; Mice; Xanthenes; Xanthones | 1998 |
Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats.
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Carbonates; Diabetes Mellitus; Glucokinase; Glucose Transporter Type 4; Glucose-6-Phosphatase; Glucosides; Hyperglycemia; Hyperinsulinism; Insulin Resistance; Liver; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Rats; Rats, Zucker | 2000 |
Antidiabetic activity of a xanthone compound, mangiferin.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Magnoliopsida; Male; Mice; Phytotherapy; Plant Extracts; Xanthenes; Xanthones | 2001 |